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Abstract
SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a heterogeneous condition combining osteoarticular
and cutaneous manifestations. Conventional treatments are mostly ineffective. We hereby report two patients, the first with an
aggressive form of disease and the second with an incomplete response to two different anti-TNF-α agents. Both were success-
fully treated with tocilizumab and ustekinumab, respectively, over a long period of time. A narrative review of a biological
therapy in SAPHO syndrome yielded very little information on the specific use of these agents. We highlight the advantages of
personalising therapy and describe emerging promising treatments for this disease.
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Introduction
Synovitis, acne, pustulosis, hyperostosis and osteitis
(SAPHO) syndrome is a rare chronic immune-mediated con-
dition characterised by combined osteoarticular and cutaneous
manifestations [1]. Not every patient presents with the full
spectrum of the disease [2]. Given its heterogeneity, diagnosis
is challenging and conventional treatments, ranging from non-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids,
antibiotics and bisphosphonates to several disease-modifying
anti-rheumatic drugs (DMARDs) such as methotrexate,
sulfasalazine or azathioprine, have yielded suboptimal re-
sponses [3, 4]. Anti-tumour necrosis factor-alpha (anti-
TNF-α) agents and interleukin-1 (IL-1) antagonists have
achieved more effective outcomes but some patients remain
refractory and may only respond in a single organ domain [4,
5]. There is scarce information on the value of more recent
biological response modifier therapies.
We first describe the follow-up of two patients with
SAPHO syndrome treated with tocilizumab and ustekinumab,
respectively. We then review all previous studies involving
patients with SAPHO treated with biological agents, synthetic
agents and cell signalling pathway inhibitors, with a special
focus on non-anti-TNF-α agents, with respect to therapeutic
outcome. We suggest the current array of biological therapies
allows for the treatment of SAPHO patients in a personalised
fashion, aiming to achieve early remission and preventing
irreversible organ damage.
Methods
Demographic data, clinical records, therapeutic options and
outcomes in patients treated with biological agents were the
focus of the case reports and literature review. The latter was
performed in a narrative form, through a PubMed search,
using the terms “SAPHO” and “syndrome” and “treatment”,
up until the 31st December 2018, with no other publication
date constraints. Additional relevant literature was hand-pick-
ed. The search was performed by two authors and resulted in a
total of 324 articles. The first selection was restricted to man-
uscripts written in English, French, Spanish and Portuguese
but only manuscripts written in English were found. Patient
reports in review articles were included but we rejected edito-
rials, commentaries, congress presentations and articles
reporting SAPHO patients not exposed to biological therapies.
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Then, chronologically, we selected every single publication
reporting clinical cases that described SAPHO syndrome pa-
tients subjected to biologicals and more recent compounds,
obtaining a total of 40 manuscripts (11 single-centre cohort
and 29 single case reports) as illustrated in the flowchart
(Fig. 1). Mendeley was used as the reference manager.
Duplicate information regarding individual patients was re-
solved. While the present study was being conducted, a series
of 45 SAPHO patients subjected to biological therapy was
published [6]. We found 22 additional cases and separately
analysed biological non-TNF-α therapy-treated patients, the
latter constituting our main research focus.
There is no unified concept of remission in SAPHO syn-
drome. When all organ systems ameliorate, response is gen-
erally considered complete. When response to therapy is di-
chotomized into cutaneous or articular, it is considered partial,
according to symptomatic relief and irrespective of organ
damage.
Results
Patient 1 case report
In 2001, a 27-year-old male, HLA B27 negative,
complained of severe sternoclavicular and left arm pain
for several years. Imaging showed bilateral clavicular and
left humerus osteosclerosis and hyperostosis; concordantly,
bone scintigraphy revealed increased uptake in both first
sternocostal and sternoclavicular joints and middle third of
the humeral shaft. Of note, the patient had suffered from
severe acne vulgaris (face and trunk) from the age of 15,
treated intermittently with doxycycline and isotretinoin
with resolution of cutaneous manifestations. Combined
NSAIDs, calcium supplementation, alendronate, weekly
methotrexate (MTX), up to 25 mg per week, and prednis-
olone (10 mg per day) failed to provide pain relief,
preventing him from working for a period of approximate-
ly 5 years. A regimen of intravenous tocilizumab (TCZ),
8 mg/kg per month, was attempted in 2011 and resulted in
complete clinical remission for the next 8 years, up to the
present time. Follow-up bone scintigraphy (2018) showed
improvement (Fig. 2). Despite erosive changes (Fig. 3),
the patient has been pain free and able to cope with a
full-time employment since TCZ onset. He refused
switching to subcutaneous formulation of TCZ and con-
tinues monthly therapy.
Patient 2 case report
In 2000, a 41-year-old female, HLA B27 negative, present-
ed with severe sternoclavicular joint synovitis. She suf-
fered from palmoplantar pustulosis for the past 15 years
which worsened dur ing the previous year wi th
polyarthralgia of the wrists, elbows, shoulders and proxi-
mal interphalangeal, metacarpophalangeal and tibiotarsal
joints. She started NSAID and weekly MTX up to 20 mg
per week, with mild clinical improvement of the peripheral
joints but no improvement regarding skin manifestations
and anterior chest pain. Bone scintigraphy showed in-
Fig. 1 Literature review
methodology flowchart
178 Clin Rheumatol (2020) 39:177–187
creased uptake on both sternoclavicular joints, first right
rib and first left sternocostal joint. In December 2011, a
regimen of adalimumab 40 mg every 2 weeks in addition
to MTX was prescribed and provided symptomatic relief.
However, the treatment had to be interrupted after 2 months
due to new onset scalp psoriasis with severe alopecia.
Fig. 2 Sequential bone
scintigraphy: Initial bone
scintigraphy images
were obtained 2 h after
radiolabelled injection. There is
increased uptake in the middle
third of the humeral shaft,
sternocostal and sternoclavicular
joints, with much less intensity at
follow-up. L = left; R = right
Fig. 3 Computerised tomography
multiplanar reconstruction at the
shoulder girdle level. Para-
coronal views show
sternoclavicular (a) and
costoclavicular (b) joint erosion
with marginal osteophytosis on
the clavicle side, accompanied by
joint space narrowing; para-axial
views reveal diffuse
osteosclerosis and mild hyperos-
tosis affecting the middle third of
both clavicles, more pronounced
on the left (c). L = left; R = right
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Treatment was switched from May 2012 to etanercept
50 mg per week, providing intermittent improvement of
joint pain but failure to resolve palmoplantar pustulosis.
A switch to ustekinumab was made in March 2016,
resulting in symptomatic sustained cutaneous and articular
disease complete remission with discontinuation of MTX
over the next 3 years (Figs. 4 and 5).
Elevated serum markers of inflammation (C-reactive
protein and ESR) normalised in both patients. Neither patient
experienced side effects.
Literature review
Our literature review found a total of 67 patients treated with
biological therapies. We selected eight manuscripts which
described a total of 19 case reports of SAPHO syndrome
for which non-TNF-α and recently developed agents includ-
ing targeted synthetic DMARDs were used. Data extraction
concerning every single patient found in the literature was
exhaustively documented according to a pre-defined proto-
col. As outlined in Table 1, most patients reported were
female (N = 14; 74%) with a mean age similar between fe-
males and males (43.2 ± 11 and 43.2 ± 14, respectively).
Except for 2 patients (#15 and #16), osteoarticular and cu-
taneous manifestations occurred in every patient, 15 of
whom presented with palmoplantar pustulosis. Overall,
anakinra, ustekinumab, secukinumab and tocilizumab were
successful in patients who were refractory to prior NSAID,
corticosteroid, conventional DMARDs (cDMARDs),
pamidronate and anti-TNF-α therapy. Of note, patients #12
and #14 failed to respond to two classes of biological
DMARDs (bDMARDs); patient #17 was refractory to three
different classes of bDMARDs and was rescued by
apremilast; tofacitinib was also successful in a single patient
(#18). Mean time from diagnosis to final treatment was only
reported for 13 patients and was highly variable (8 ± 6 years).
After a mean follow-up of 8 ± 6 months, only four patients
had failed to achieve clinical remission (#7, 9, 10, 14).
We pooled all patients that ever switched to a second
biological therapy (n = 18), consisting of those that
switched between anti-TNF-α drugs (n = 5) and another
group that switched to a different class of biological agent
(n = 13, 12 taken from Table 1). Full remission was de-
scribed in 72% (n = 13/18), three patients failing to re-
spond and two patients only achieving partial remission.
Of note, novel or aggravating cutaneous reactions oc-
curred in 8 patients (44%) and these were described with
every class of bDMARD (Table 2). Paradoxical psoriasis
reactions were observed in 2 patients (one under
ustekinumab and another under secukinumab–#9 and
14). A third patient had a local reaction after an etanercept
injection and a pustular skin rash consistent with a drug
hypersensitivity reaction during secukinumab treatment.
Four patients under infliximab treatment had cutaneous
reactions namely a skin flare, allergic urticaria, a psoriatic
rash and worsening of palmoplantar pustulosis lesions that
resolved after treatment discontinuation. A single patient
developed an aseptic abscess during tocilizumab treatment
remaining unclear whether this was an adverse event or a
complication of SAPHO syndrome.
The remaining 42 patients subjected to therapy with a
single anti-TNF-α comprised 14 males and 28 females
(Table 3). Mean age was slightly higher in females than
males (42.4 ± 12 and 35.1 ± 11, respectively). Mean follow-
up was 16.8 ± 25 months and most patients were treated
with infliximab (n = 23) followed by etanercept (n = 11),
adalimumab (n = 7) and certolizumab pegol (n = 1). They
had been followed for an average of 17 months, the longest
having been in partial remission, on infliximab, for 11 years.
Every patient had osteoarticular manifestations. Overall,
complete, partial or no remissions were observed in 30, 10
and 2 patients respectively. For those patients with both
osteoarticular and cutaneous manifestations (n = 35), the
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Fig. 4 Plantar pustulosis during etanercept treatment (a) and after ustekinumab (b)
presence of cutaneous manifestations was not associated to a
lack of response to anti-TNF-α agents, and 24 of such pa-
tients (69%) were considered complete responders. There
was no statistically significant therapeutic benefit associated
to therapy with either infliximab or etanercept. Significantly,
partial remissions to anti-TNF-α therapy were always due to
a lack of response in the cutaneous domain, corresponding
to 10/35 patients (29%).
Discussion and conclusions
SAPHO syndrome is rare; there are no controlled clinical
trials and its aetiology and pathogenesis remains unknown.
In general, as SAPHO is a heterogeneous condition, a lack
of specific evaluation tools—as regards to both global and
organ-specific disease activity and damage—hampers
classification of treatment responses. The narrative review
highlights the wide variety of pharmacological therapies
that have been attempted to treat SAPHO and suggests that
the rationale behind each treatment is based on refractori-
ness to a previous therapy and/or availability of a new
class of drug.
Approximately half of the anti-TNF-α-treated patients
(n = 21) were reported between 2012 and 2015, after which
time only six patients were described. Anti-IL-1 therapy
was used as early as 2010 in a single patient, and in a case
series of five patients in 2012 but generally overlooked
thereafter. Use of other non-anti-TNF-α is described from
2016, underlying the younger age group of those treated
with more recently marketed bDMARDs and targeted syn-
thetic DMARDs. Lack of response to anti-TNF-α therapy
was described with respect to SAPHO patients presenting
with cutaneous manifestations, most frequently with
palmoplantar pustulosis. This is in stark contrast with the
overwhelming success of diverse non-anti-TNFα thera-
pies, namely anakinra, ustekinumab, secukinumab, toci-
lizumab, tofacitinib and apremilast. While using a single
database may be considered a limitation to the literature
review, our strengths remain with the fact that we have
undertaken the longest case-based review on SAPHO syn-
drome and the first focusing non-anti-TNFα therapies.
Our two case reports mirror the literature review with re-
spect to a long delay from diagnosis to onset of effective
therapy but highlight an important difference. The first patient
had highly active osteoarticular disease and damage (erosions,
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Fig. 5 Sequential bone scintigraphy: Images obtained 5 min after
intravenous injection of technetium-99m demonstrates slightly increased
uptake (arrow) at the sternocostal joint of the first rib on the right, anterior
and posterior views (arrows) (a); 2 h after injection there is increased
uptake at the medial surface of the first right rib, sternoclavicular joints
and left sternocostal joint of the first rib with progressive reduction over
an eight-year follow-up (b); R = right; L = left
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hyperostosis and osteitis) that severely impacted his daily ac-
tivities and the disease was non-responsive to longstanding
MTX. Tocilizumab was chosen on the basis of its effect on
inhibition of osteoclast activity [46] and even though delayed
implementation failed to prevent irreversible joint damage,
therapy proved to be highly effective. Palmoplantar
pustulosis, refractory to anti-TNF-α therapy in the second
patient, was treated with ustekinumab, based on reports of
its efficacy specifically regarding palmoplantar psoriasis [47]
and psoriatic arthritis [48]. While we recognise that both toci-
lizumab and ustekinumab had become commercially available
at the time treatments were started, the rationale behind their
successful use must be emphasised. Both therapies were cho-
sen to target specific clinical manifestations. Moreover, in
both patients, drug survival was maintained throughout the
follow-up.
Paradoxical skin lesions such as palmoplantar pustulosis
may be difficult to distinguish from a psoriatic rash just as
both may be due to a flare of SAPHO syndrome or induced
by anti-TNF therapy [49]. Of note, in the literature review,
adverse cutaneous reactions were considered to represent ex-
acerbations or lesions of a paradoxical nature, in three and five
patients, respectively. In every single case, agent discontinua-
tion was followed by a switch to an alternative bDMARD,
akin to the course of action taken when the second patient
developed severe scalp psoriasis.
Until the time comes for treatment to be based on
scientific judgement, our case reports and literature re-
view suggest that, in a manner similar to the latest rec-
ommendations for systemic rheumatic and cutaneous
conditions [50], patients who are unresponsive to
cDMARDs should be offered early biological therapy,
tailored to the prevailing clinical phenotype. Analysis
of the appropriateness of therapy in SAPHO syndrome
seems jeopardized owing to the absence of dedicated
scores to describe global disease activity and severity
of clinical osteoarticular and cutaneous manifestations.
In addition, strict definitions of remission for each organ
domain need to be developed. Patients with SAPHO
should be carefully observed for paradoxical and adverse
cutaneous events and furthermore biologicals should be
switched in order to achieve the lowest possible disease
activity and prevent irreversible damage. Finally, we
wish to underline that SAPHO may be a severely
prolonged incapacitating condition, reinforcing a recom-
mendation to avoid therapeutic delay and highlighting
the ongoing challenge of a treat to target approach.
Our case reports illustrate the successful use of biologi-
cal therapies chosen on the basis of specific clinical
manifestations and the longest known follow-up in clin-
ical remission for tocilizumab and ustekinumab in
SAPHO syndrome.
Table 2 SAPHO syndrome patients subjected to switch between biological agents, describing rationale for switching and therapeutic outcomes
Reference # in Table 1 Previous
biological agent
Rationale for switching
between biologicals
Final treatment Outcome
Wendling [8] 5 INF Lack of response ANK CR
6 INF, ETN, ADA Lack of response ANK CR
7 ADA, ETN Lack of response ANK NR
Cornillier [9] 8 ETN, ADA Lack of response UST CR
Wendling [10 9 ADA, INF Lack of response UST NR
10 ADA Lack of response UST NR
12 ADA, INF, UST Lack of response SEC PR
13 INF, ADA Lack of response SEC CR
14 INF, ANK Lack of response SEC NR
Adamo [12] 17 ETN, UST, ADA, SEC ETN–local reaction to ETN; UST–upper airway infections;
ADA–PPP flare; SEC–pustular skin rash
APR CR
Yang [13] 18 ETN Lack of response TFC CR
Daoussis [6] 19 INF, ADA Lack of response SEC CR
Wagner [14] – INF Bronchospasm ETN CR
Abdelghani [15] – INF INF–osteoarticular and skin flare ETN CR
– INF INF–allergic urticarial reaction ADA PR
– INF INF–psoriatic rash ETN CR
Arias-Santiago [16] – INF INF–worsening of skin lesions ADA CR
Fujita [17] – TCZ TCZ–aseptic abcess INF CR
#, patient number; PPP, palmoplantar pustulosis; INF, infliximab; ETN, etanercept; ADA, adalimumab; TCZ, tocilizumab; UST, ustekinumab; SEC,
seccucinumab; ANK, anakinra; APR, apremilast; TFC, tofacitinib; CR, complete remission; PR, partial remission; NR, no remission
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